Keele, UK, 25 October 2007, Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces an agreement with the University of Rochester Medical Center (URMC) to develop a scalable production process for a novel human immunodeficiency virus (HIV) vaccine platform utilizing URMC’s herpes simplex virus (HSV) amplicon vector technology. Under the agreement, Cobra will perform process optimization and scale-up studies to support GMP production of amplicons for clinical supply.
